The Australian market faces a cautious outlook, with the ASX struggling to regain momentum amid mixed signals from global markets and sector-specific performances. In such times, identifying stocks with potential becomes crucial, especially in areas like penny stocks—an investment category that, while sometimes seen as outdated, remains relevant for its potential growth opportunities. These smaller or newer companies can offer significant value when backed by strong financial health and fundamentals.

Top 10 Penny Stocks In Australia

Name Share Price Market Cap Financial Health Rating Alfabs Australia (ASX:AAL) A$0.48 A$137.56M ★★★★★☆ EZZ Life Science Holdings (ASX:EZZ) A$2.13 A$100.48M ★★★★★★ Dusk Group (ASX:DSK) A$0.885 A$55.11M ★★★★★★ IVE Group (ASX:IGL) A$2.86 A$442.23M ★★★★★☆ Veris (ASX:VRS) A$0.078 A$40.38M ★★★★★★ SHAPE Australia (ASX:SHA) A$4.11 A$338.44M ★★★★★★ West African Resources (ASX:WAF) A$3.04 A$3.47B ★★★★★★ Tasmea (ASX:TEA) A$4.10 A$1B ★★★★★☆ Praemium (ASX:PPS) A$0.79 A$377.78M ★★★★★★ SKS Technologies Group (ASX:SKS) A$2.76 A$312.07M ★★★★★★

Click here to see the full list of 442 stocks from our ASX Penny Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Critica

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Critica Limited is involved in the exploration and development of mineral resources in Australia, with a market capitalization of A$67.45 million.

Operations: The company has not reported any revenue segments.

Market Cap: A$67.45M

Critica Limited, with a market cap of A$67.45 million, is pre-revenue and unprofitable, making it challenging to compare its growth to the broader Metals and Mining industry. Despite being debt-free for five years and having short-term assets that cover liabilities, the company faces a cash runway of less than one year if free cash flow continues to decline at historical rates. The board's average tenure is just 1.3 years, indicating inexperience. While shareholder dilution hasn't been significant recently, the stock remains highly volatile with a negative return on equity at -69.47%.

Get an in-depth perspective on Critica's performance by reading our balance sheet health report here. Gain insights into Critica's past trends and performance with our report on the company's historical track record.ASX:CRI Debt to Equity History and Analysis as at Sep 2025

Cettire

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Cettire Limited operates as an online luxury goods retailer in Australia, the United States, and internationally, with a market cap of A$131.53 million.

Operations: The company generates revenue primarily through online retail sales, amounting to A$742.11 million.

Story Continues

Market Cap: A$131.53M

Cettire Limited, with a market cap of A$131.53 million, is an online luxury goods retailer experiencing financial challenges. Despite generating significant revenue of A$742.11 million, the company reported a net loss of A$2.65 million for the year ended June 30, 2025. It is debt-free but has short-term liabilities exceeding its assets by A$28.7 million and remains unprofitable with a negative return on equity of -7.39%. Recent board changes may impact strategic direction as management tenure averages only 1.2 years, indicating potential instability in leadership amidst high share price volatility over recent months.

Click to explore a detailed breakdown of our findings in Cettire's financial health report. Understand Cettire's earnings outlook by examining our growth report.ASX:CTT Financial Position Analysis as at Sep 2025

NobleOak Life

Simply Wall St Financial Health Rating: ★★★★★★

Overview: NobleOak Life Limited operates in Australia, focusing on underwriting life insurance products, with a market cap of A$138.27 million.

Operations: The company generates revenue through three segments: Genus (A$10.99 million), Direct (A$88.92 million), and Strategic Partnerships (A$335.21 million).

Market Cap: A$138.27M

NobleOak Life Limited, with a market cap of A$138.27 million, operates without debt and is trading below its estimated fair value. Despite experiencing a decline in net income to A$7.12 million for the year ended June 30, 2025, the company maintains high-quality earnings and forecasts suggest a robust annual profit growth of 27.82%. The board is experienced with an average tenure of 5.5 years; however, management's shorter tenure indicates potential leadership challenges. NobleOak's short-term assets significantly exceed both its short- and long-term liabilities, providing financial stability amidst lower profit margins compared to last year.

Navigate through the intricacies of NobleOak Life with our comprehensive balance sheet health report here. Explore NobleOak Life's analyst forecasts in our growth report.ASX:NOL Financial Position Analysis as at Sep 2025

Where To Now?

Click here to access our complete index of 442  ASX Penny Stocks. Ready For A Different Approach? The latest GPUs need a type of rare earth metal called Dysprosium and there are only 29 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ASX:CRI ASX:CTT and ASX:NOL.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]